Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2014

View Archived Issues

Phase I study of Cellceutix's Prurisol meets primary endpoint

Cancer Research UK and Cancer Research Technology join forces with Astellas Pharma

Tufts Medical Center and ATON Partners form neurological-focused company CereVasc

Cellectar Biosciences files IND to evaluate I-131-CLR-1404

First patients enrolled in phase II trial of photofrin PDT for mesothelioma

Biodel reports phase IIa data for BIOD-531 in patients with type 2 diabetes

Sanofi and MannKind enter into global licensing agreement for Afrezza

Optimization of RORc inverse agonists from Genentech

Topline results from first pivotal study of Rayaldee for secondary hyperparathyroidism

BMS-986118, a novel potent dual-acting GPR40 agonist for the treatment of diabetes

PDE10A inhibitors for the treatment of schizophrenia

Human Longevity and Celgene Cellular Therapeutics sign agreement for PSC-100

Salix Pharmaceuticals reports topline data from TARGET 3 trial

Development of a rapid point-of-care diagnostic test EBOV and SUDV detection

Investigators from Emory University disclose Cas9 gene therapy

Japan investigators report development of hLAT1 inhibitors

Bristol-Myers Squibb discloses new NS5B inhibitors

In vivo results demonstrate high potential of FR-104 for clinical transplantation

Step-wise optimization of an anticancer MAb for maximum inhibitory effect

CureDuchenne supports Prosensa's efforts to advance DMD pipeline

Oncothyreon to use Alpine's protocell technology for delivery of molecular therapeutics

FDA grants orphan drug designation to OncoSynergy's OS-2966 for glioblastoma

Amarantus Bioscience collaborates with the Buck Institute for Research on Aging

Venaxis updates on progress of appendicitis risk test in U.S.

Celltrion files for FDA approval of infliximab biosimilar

Cempra initiates phase III trial of solithromycin to treat gonorrhea

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...